anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Temporomandibular disorder (TMD) and fibromyalgia syndrome (FMS) may present as comorbid conditions, but treatment options are ineffective. The purpose of this study was to investigate whether valproate (VPA) attenuates somatic hyperalgesia induced by orofacial inflammation combined with stress, which represents a model of pain associated with TMD and FMS comorbidity, and to explore the potential mechanisms. The results showed that VPA inhibited somatic hyperalgesia induced by orofacial inflammation combined with stress, and down-regulated the interleukin-6 (IL-6) expression in the L4-L5 spinal dorsal horn of female rats. The anti-nociceptive effect of VPA was blocked by single or 5 consecutive day intrathecal administration of recombinant rat IL-6. Orofacial inflammation combined with stress up-regulated the ratio of phosphorylated signal transducer and activator of transcription 1 (p-STAT1) to STAT1 (p-STAT1/STAT1) in the spinal cord. VPA did not affect the STAT1 expression, while it down-regulated the ratio of p-STAT1/STAT1. The expression of STAT3 and the ratio of p-STAT3/STAT3 were not affected by orofacial inflammation combined with stress and VPA treatment. Intrathecal administration of exogenous IL-6 up-regulated the ratio of p-STAT1/STAT1. These data indicate that VPA attenuated somatic hyperalgesia induced by orofacial inflammation combined with stress via inhibiting spinal IL-6 in female rats, and the mechanism may involve the alteration of activation status of spinal STAT1. Thus, VPA may be a new candidate analgesic that targets IL-6 and STAT1 for the treatment of pain associated with the comorbidity of TMD and FMS.
Up to 20 subjects will be enrolled at 1 study center. Subjects will be enrolled into one of 2 groups. Group A will receive split face treatments with the Potenza and Morpheus. Group B will receive treatments on the face, abdomen, and/or back with Potenza and/or Morpheus. Subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. Subjects will receive up to 3 treatments with Potenza (and Morpheus).
Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
PURPOSE: A manufacturing method of fermented bellflower is provided to increase the content of platycodin D and reduce Gomi of bellflower characteristic. CONSTITUTION: Grind a bellflower. Sterilize a grinded bellflower. Cultivate sterilized bellflower as a yeast. Put 50 to 100g of yeast per 1kg of cultivated bellflower and cultivate it for two to four days at 25 to 35 deg. C. Filter and concentrate the cultivated bellflower. Pulverize the concentrated bellflower by lyophilizating it. A yeast if separated from malt which is selected from the group that composed of Saccharomyces cerevisiae, Saccharomyces ellipsoideus, Saccharomyces coreanus, Saccharomyces carlsbergensis, Zygosaccharomyces major Saccharomyces lactics, Saccharomyces rouxii and Hansenula anomala. [Reference numerals] (AA) Before fermentation; (BB) Fermenting malt; (CC) Cultivating yeast; (DD) Fermenting malt after cultivating yeast
A lower initial dose of 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with hepatic or renal impairment, for certain drug interactions that increase risperidone plasma concentrations [see Drug Interactions (7.11)] or in patients who have a history of poor tolerability to psychotropic medications. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.

Oral risperidone (or another antipsychotic medication) should be given with the first injection of Risperidone for Extended-Release Injectable Suspension and continued for 3 weeks (and then discontinued) to ensure that adequate therapeutic plasma concentrations are maintained prior to the main release phase of risperidone from the injection site [see Clinical Pharmacology (12.3)].

Upward dose adjustment should not be made more frequently than every 4 weeks. The clinical effects of this dose adjustment should not be anticipated earlier than 3 weeks after the first injection with the higher dose.

In patients with clinical factors such as hepatic or renal impairment or certain drug interactions that increase risperidone plasma concentrations [see Drug Interactions (7.11)], dose reduction as low as 12.5 mg may be appropriate. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.

Do not combine two different dose strengths of Risperidone for Extended-Release Injectable Suspension in a single administration.
Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) \> 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C \< 9.0%. They will receive the active comparator (metformin).
The present invention relates to a protein receptacle into which various exogenous polyamino acid sequences can be inserted simultaneously for expression in various systems and for various uses. The present invention relates to polynucleotides which can generate the previously mentioned protein receptacle. The present invention also relates to a vector and expression cassette comprising the previously mentioned polynucleotide. The present invention also relates to a cell comprising the previously mentioned vector or expression cassette. The present invention also relates to a method for producing said protein receptacle and identifying pathogens or diagnosing diseases in vitro. The present invention also relates to the use of said protein receptacle and kit comprising said protein receptacle for diagnosis or as vaccine compositions.
The overarching goal of the project is to improve access to early abortion by reducing barriers that patients face obtaining services. Currently, patients are prescribed and receive Mifeprex® and misoprostol directly from a clinician, who evaluates patients for medical eligibility and contraindications. The Mifeprex® may be taken in the facility or at home, and the misoprostol is taken 24-48 hours later at home. The FDA recommends a follow-up visit, which can be over the phone.

The purpose of this study is to pilot test the model of advance provision of medication abortion (MAB). In this model, patients at risk of unintended pregnancy and with a desire to avoid pregnancy will be assessed by a clinician and provided counseling on pregnancy recognition and testing, as well as how to administer MAB at home. For this pilot study, only patients who have previously had a MAB will be included, since this population has reported the highest interest in the model, and they are also already familiar with how to use the medications. The clinician will provide Mifeprex® and misoprostol to the patient at the time of counseling in case the patient becomes pregnant and wants to terminate the pregnancy using the medications up to 10 weeks gestation. Patients will contact a study clinician for an over-the-phone assessment of eligibility for MAB, including assessment of gestational age, before self-administration of Mifeprex® and misoprostol, and then attend a follow-up visit with the clinician.

Patients will sign the Danco Patient Agreement Form prior to receiving the medication. Clinicians dispensing the medications will have signed the Prescriber Agreement Form, and the medications will be dispensed in a clinic or hospital. Study investigators will monitor participant activity through surveys throughout the study. Participants will be given clear instructions on study participation and returning unused medications in an appropriate time frame. Clinicians will also re-evaluate participants by telephone before they take the medications and evaluate them in person at a subsequent follow-up visit.
Tissue injury after angioplasty is likely due to micro-emboli from mechanical trauma to a thrombotic lesion during angioplasty. In response to the ischemia sPLA2, possibly localized within atherosclerotic vascular tissue as well as from macrophages and monocytes, is released. Following ischemia-induced release, sPLA2 can bind to ischemically challenged cardiomyocytes and adversely affect their survival either directly through toxic effects on cardiomyocytes or indirectly by facilitating inflammation. It may be possible through sPLA2 inhibition to salvage non-lethally jeopardized cells following an ischemic episode thereby reducing the infarcted area and amount of tissue damage. Previous studies in patients with unstable angina support this hypothesis, and conclude that sPLA2 levels can be used to predict clinical outcomes. We hypothesize that sPLA2 inhibition with A-002 will reduce myocardial injury post-angioplasty.

Substudy - Peripheral vascular ultrasound should be done prior to receiving study drug and 24h post-PCI. Coronary endothelial function will be assessed at the time of PCI.
In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded RNA-specific adenosine deaminases, or ADAR, enzymes. In alternative embodiments, the invention provides compositions and methods for treating, ameliorating or preventing diseases and conditions responsive to the inhibition of cell differentiation and/or self-renewal of dysfunctional cells, cancer cells, leukemia cells, hematopoietic stem cells or cancer stem cells, e.g., leukemia or Chronic Myeloid Leukemia (CML). In alternative embodiments, the invention provides compositions and methods for inhibiting a Sonic Hedgehog (Shh) pathway, e.g., by using a Smoothened (SMO) protein inhibitor. In alternative embodiments, the invention provides compositions and methods for measuring or determining, or predicting, chronic myelogenous leukemia (CML) progression, Leukemic Stem Cell (LSC) generation and/or tyrosine kinase inhibitor resistance. In alternative embodiments, the invention provides compositions and methods for determining or measuring the effectiveness of a treatment, a drug, a therapy or a diet for eliminating, killing or reducing the amounts of a leukemic stem cell (LSC) or cells.
This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
The identification of unknown human remains is a significant and ongoing challenge in South Africa, worsened by the country's high murder rate. The rate of decomposition in South Africa is significantly influenced by vertebrate scavenging, which, if not considered, can impede the accurate estimation of the post-mortem interval. Scavenging patterns vary greatly depending on the environment and ecological region, and there is limited data for the Western Cape province. To address this gap, two clothed and uncaged pig carcasses weighing 60 kg each were placed in the field in July 2021 and January 2022, respectively. Motion-activated infrared-capable trail cameras were used to observe decomposition, scavenger species, and their activities. Additionally, a comparative sample of 16 unclothed carcasses deployed between 2014 and 2016 in the same habitat were analyzed to assess the impact of clothing and biomass load. The study found three main results: (1) Regardless of habitat or biomass load, it took significantly less time to reach decomposition milestones (25%, 50%, and 75%) during the summer season; (2) the presence of mongoose scavengers had a greater impact on the time required to reach milestones during winter compared to summer; and (3) single carcass deployments reached the milestones faster than multi-carcass deployments in both seasons. This research highlights the potential inaccuracy of current methods for estimating the post-mortem interval when scavenging activity is not considered or documented in the underlying experimental data, particularly for environments or ecological biomes where scavengers actively impact decomposition rates.
Despite the availability of a wide range of antidepressant drugs, 30% to 40% of patients with major depression fail to respond to first-line antidepressant (e.g., selective serotonin reuptake inhibitors \[SSRIs\]) treatment, despite adequate dosage, duration, and compliance. Furthermore, these medications may take weeks to months to achieve their full effects, and in the meantime, patients continue to suffer from their symptoms and continue to be at risk of self-harm as well as harm to their personal and professional lives. Thus, there is a clear need to develop novel and improved therapeutics for treatment-resistant major depression that are more effective and have a rapid onset of action. Preclinical and clinical studies suggest that antidepressants with a combined mechanism of action (e.g., combination of a selective serotonin-reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor) may be more effective than either agent alone in achieving remission (Nelson et al 2004). Thus, it stands to reason that other combinations of antidepressants with other mechanisms of action when combined may have a synergistic effect that is superior to an antidepressant with a single mechanism of action. Preclinical and clinical studies suggest that the dopaminergic system may play a major role in the pathophysiology of depression. Preclinical studies suggest synergistic antidepressant effects with the combination of a SSRI and a selective D3 receptor agonist in animal models of depression. Similarly, preliminary clinical studies suggest synergism with combination treatment that affects the serotonin and dopamine systems. Together, these data suggests that treatments which affect the serotonin and dopamine systems will be more effective than agents which use a single mechanism. We propose to compare the combination of a selective dopaminergic agonist and a SSRI in patients with treatment-resistant major depression. To our knowledge, this will be the only controlled double-blind study to date that will examine the efficacy of a serotonin and dopamine combination given from the start of treatment.

Patients, ages 18 years or older, with a diagnosis of major depression (without psychotic features), will be randomized to the combination of a selective dopaminergic receptor agonist and a SSRI or either drug alone for a period of 6 weeks. Acute efficacy will be determined by demonstrating a greater remission rate using specified criteria. Approximately 115 patients with acute major depression will be enrolled in the study.
Increased inflammatory cytokines and matrix metalloproteinases (MMPs) have been recently implicated in migraine. Inflammation may be a key player in the pathophysiology of migraine by altering blood-brain barrier (BBB) function. As an inflammation induced MMP, MMP-9 is involved in both BBB disruption and neuropathic pain, and is largely derived by neutrophil degranulation during neutrophil-BBB interaction. The tetracycline group of antibiotics may suppress MMP production and neutrophil degranulation. This study aims to investigate known neuroinflammatory biomarkers with a focus on BBB breakdown during acute migraine attacks and assess marker responses to conventional treatment (triptans) and novel MMP targeted therapy (doxycycline). This pilot project data will supplement future projects investigating novel therapeutic strategies such as MMP inhibitors in both migraine acute treatment and prevention.
Participants in this condition will receive Treatment-as-usual (TAU) the first four weeks post trauma, and after Condensed internet-delivered prolonged exposure (CIPE). Participants will receive CIPE between 4 and 10 weeks after trauma. In CIPE, participants are encouraged to have daily contact with their therapist through a secured email system within the platform. Therapists are also available for phone sessions. Total therapist contact for each participant is generally less than 60 minutes during the whole program. Participants are expected to work on intervention tasks for six hours each week and to complete the intervention in three weeks. The intervention is delivered by psychosocial crisis teams' staff in 14 municipalities in the central-eastern part of Norway. Content, frequency, and quantity of the CIPE+TAU-condition will be measured.
Spinal muscular atrophy (SMA) is a severe, debilitating disease and is an important source of morbidity and mortality of children. Novel disease modifying therapies can alter the natural course of the disease. However, many aspects of their action remain unknown. Metabolomics is the large-scale study of metabolites, within cells, biofluids, tissues or organisms. Collectively, these small molecules and their interactions within a biological system are known as the metabolome.

The aim of this study is to evaluate whether the metabolome of patients with SMA before the initiation of disease modifying therapy with nusinersen differs from the metabolome of healthy individuals. Next, we would like to asses whether tretament with nusinersen alters the metabolome of patients with SMA. Utilizing metabolomics, we would like to assess whether we can identify parameters reflecting the state of the disease in a particular patient, and parameters with diagnostic and/or prognostic value. Using metabolomics, we will aim to identify SMA patients that will positively respond to gene therapy.
Virus-analog particles are predominantly produced recombinantly. Recombinant expression of capsomers in Escherichia coli makes it possible to obtain non-assembled capsomers which can be assembled in vitro. However, the degree of assembly is low. In fact, in vitro assembly into virus-analog particles is prevented if the macromolecules are bound to the capsomers. Complexes with macromolecules can only be obtained by interaction of the macromolecules with the already assembled virus-analog capsomers. The degree of packing of the macromolecules is nevertheless low. Virus-analog particles are produced by means of a method for the production of virus-analog particles by in vitro assembly of capsomers or capsomers, biologically active macromolecules being bound to the charged amino acids of said capsomers with simultaneous packing to macromolecules in the presence of non-ionic stabilizers. Said complexes are suitable vectors for gene therapy.
Communication skills focused psychoeducation group will be given a communication skills-focused psychoeducation program for eight weeks, one session per week, for a total of eight sessions. The number of sessions was planned with reference to the study in which the effect of the psychoeducation program on general health and communication skills in caregivers of individuals with schizophrenia was investigated.Session groups will be formed from a single session of 60-90 minutes for each topic.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a "functional food/environmental repairing agent expected to exhibit a decomposition function of various steroids" by using a fermented food such as kimutsi.  <P>SOLUTION: This functional food/environmental repairing agent is provided by utilizing cholesterol-decomposing microorganisms or their cholesterol-decomposing enzymes separated from fermented foods such as the kimutsi, pickles with sake lees, soybean paste, fermented soybean using Bacillus natto by using an accumulative culturing method. Further, on using as the functional food, it may be mixed with a suitable carrier, or has shapes of capsules or a medicinal bags. Also, a method for producing the food by adding the separated "cholesterol-decomposing microorganisms derived from the fermented food or their decomposing enzymes" in the process of producing the fermented food such as the kimutsi, is useful. In such cases, simultaneously adding of either one of lipase and protease or both of them may be allowed. As an object for the decomposition, various steroidal substances such as estrogen, androgen, cortisol, (related to diseases) may be selected.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Bimolecular-membrane vesicles capable of undergoing a phase transition, wherein the membranes comprise, as components thereof, (a) a C6-20 fatty acid salt, (b) an alcohol or amine compound having a C6-20 aliphatic chain, and (c) a synthetic lipid or phospholipid capable of forming a bimolecular membrane.  Preferably, the bimolecular-membrane vesicles further contain (d) a tertiary amine as a component of the membranes. Also provided is a method of causing bimolecular-membrane vesicles to undergo a phase transition, which comprises the step of adding to the bimolecular-membrane vesicles either a dehydrating condensation agent or dehydrating condensation agent precursor having the property of accumulating at the interface. Thus, a lipid in a molecular aggregate form can be caused to undergo a chemical change and a resultant change in physical property or form. The timing of a phase transition such as membrane fusion can be controlled. In the membrane fusion, for example, it can be conducted without leaking out the contents of the bimolecular-membrane vesicles.
All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerability. Re-titration was done to maintain the blinding of the double-blind study (E2020-A001-219). Doses could be decreased due to tolerability and could be increased or decreased to maintain a maximum dose of 0.1 to 0.2 mg/kg/day based on the participant's weight at clinic visits during the study duration.
PURPOSE: To provide a tooth surface treating agent for dental glass ionomer cement, composed of an α,β-unsaturated carboxylic acid polymer having a specific property, a compound containing a specific element and water and effective for increasing and stabilizing the adhesive force to the dentine. CONSTITUTION: This treating agent contains 1-80 pts.wt. of an α,β-unsaturated carboxylic acid polymer (e.g. polyacrylic acid) having a weight-average molecular weight of 1,000-40,000, 0.01-30 pts.wt. of a compound containing one or more kinds of elements selected from aluminum, iron, tin and calcium (e.g. aluminum oxalate) and 20-100 pts.wt. of water as active components. The agent is further incorporated with 0.0001-5 pts.wt. of a food color and 0.1-30 pts.wt. of a thickener. The agent for the treatment of tooth surface is applied in the case of using a dental glass ionomer cement and is effective for dissolving and removing a smear layer remarkably inhibiting the adhesion of a dental material. It is also effective for increasing and stabilizing the adhesive force between the glass ionomer cement and the dentine.  It is milder than phosphoric acid, leaves the smear plug in the pores and suppresses the stimulation and injury of dental pulp.